Can axillary dissection be avoided by improved molecular biological diagnosis?

Acta Oncologica

Volumn 39, Issue 3, 2000, Pages 319-326

  Lindahl, T ^a   Engel, G ^a   Ahlgren, J ^a   Klaar, S ^a   Bjohle, J ^a   Lindman, H ^a   Andersson, J ^a   Von Schoultz, E ^a   Bergh, J ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CATHEPSIN D; NERVE CELL ADHESION MOLECULE; PROTEIN P53; VASCULOTROPIN;

AXILLARY LYMPH NODE; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER STAGING; CLINICAL TRIAL; CONFERENCE PAPER; HUMAN; INTERMETHOD COMPARISON; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; TREATMENT PLANNING; TUMOR VOLUME;

EID: 0033870072     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/028418600750013087     Document Type: Conference Paper

References (97)

1. Breast cancer: Risk of axillary recurrence in node-negative patients following partial dissection of the axilla
2. Assessment of morbidity from complete axillary dissection
3. The effect of pre- and postmastectomy radiotherapy on the degree of edema, shoulder-joint mobility, and gripping force
4. Somatic sensation and discomfort in the arm of post-mastectomy patients
5. Arm problems and psychological distress after surgery for breast cancer
6. Arm function after axillary dissection for breast cancer: A pilot study to provide parameter estimates
7. Post-mastectomy radiotherapy following adjuvant chemotherapy and autologous bone marrow transplantation for breast cancer patients with greater than or equal to 10 positive axillary lymph nodes Cancer and Leukemia Group B
8. Dosage of adjuvant G-CSF (filgrastim)-supported FEC polychemotherapy based on equivalent haematological toxicity to high-risk breast cancer patients
9. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: Findings from NSABP B-18
10. Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Results of a randomized trial in a single centre
11. Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery preliminary results of a randomised trial: S6
12. Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer
13. International consensus panel on the treatment of primary breast cancer V: Update 1998
14. Axillary dissection: When and how radical?
15. Prediction of axillary lymph node metastases in a screened breast cancer population
16. Prediction of axillary lymph node status in breast cancer patients by use of prognostic indicators
17. Treatment of early-stage breast cancer
18. Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes
19. Lymphatic mapping and sentinel lymphadenectomy for breast cancer
20. Evidence for a novel gene associated with low tumor metastatic potential
21. Reduced tumor incidence, metastatic potential, and cytokine responsiveness of nm23-transfected melanoma cells
22. Transfection of human nm23-H1 into the human MDA-MB-435 breast carcinoma cell line: Effects on tumor metastatic potential, colonization and enzymatic activity
23. Nucleoside diphosphate kinase from human erythrocytes. Structural characterization of the two polypeptide chains responsible for heterogeneity of the hexameric enzyme
24. Association of low nm23 RNA levels in human primary infiltrating ductal breast carcinomas with lymph node involvement and other histopathological indicators of high metastatic potential
25. NDP-K/nm23 expression in human breast cancer in relation to relapse, survival, and other prognostic factors: An immunohistochemical study
26. Expression of nucleoside diphosphate kinase/nm23 gene product in human pancreatic cancer: An association with lymph node metastasis and tumor invasion
27. High levels of p19/nm23 protein in neuroblastoma are associated with advanced stage disease and with N-myc gene amplification
28. Induction of nm23 gene expression in human colonic neoplasms and equal expression in colon tumors of high and low metastatic potential
29. Structure and function of the p53 tumor suppressor gene: Clues for rational cancer therapeutic strategies
30. Systemic gene therapy with p53 reduces growth and metastases of a malignant human breast cancer in nude mice
31. In vivo molecular therapy with p53 adenovirus for microscopic residual head and neck squamous carcinoma
32. Comparison between p53 protein measurements using the luminometric immunoassay and immunohistochemistry with detection of p53 gene mutations using cDNA sequencing in human breast tumors
33. The p53 gene in breast cancer: Prognostic value of complementary DNA sequencing versus immunohistochemistry
34. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy
35. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer
36. Gene therapy for non-small cell lung cancer: A preliminary report of a phase I trial of adenoviral p53 gene replacement
37. Mechanisms of drug resistance
38. Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients
39. p53 protein accumulation and response to adjuvant chemotherapy in pre-menopausal women with node-negative early breast cancer
40. Mutations in the p53 gene predict the clinical outcome of adjuvant therapy in node-positive patients with early breast cancer
41. Expression of drug resistance proteins in breast cancer, in relation to chemotherapy
42. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer
43. Subgroups of p53 mutations may predict the clinical behaviour of cancers in the breast and colon and contribute to therapy response
44. Clinical studies of p53 in treatment and benefit of breast cancer patients
45. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1
46. Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression
47. Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma
48. Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer
49. Tumor angiogenesis: A new significant and independent prognostic indicator in early-stage breast carcinoma
50. Tumor angiogenesis is an independent prognostic indicator in primary breast carcinoma
51. Microvessel quantitation and prognosis in invasive breast carcinoma
52. Comparison of different immunohistochemical methods in the assessment of angiogenesis: Lack of prognostic value in a group of 77 selected node-negative breast carcinomas
53. Prognostic significance of microvessel density in lymph node negative breast carcinoma
54. Assessment of tumour vascularity as a prognostic factor in lymph node negative invasive breast cancer
55. Tumor angiogenesis as a prognostic assay for invasive ductal breast carcinoma
56. The metastatic phenotype-prognostic implications
57. Expression of E-cadherin cell adhesion molecules in human breast cancer tissues and its relationship to metastasis
58. Dysregulation of the E-cadherin/catenin complex by irreversible mutations in human carcinomas
59. Expression of the metalloproteinase matrilysin in DU-145 cells increases their invasive potential in severe combined immunodeficient mice
60. Expression of matrix metalloproteinase genes in transformed rat cell lines of high and low metastatic potential
61. Prognostic significance of stromelysin 3, gelatinase A, and urokinase expression in breast cancer
62. Stromelysin 3 belongs to a subgroup of proteinases expressed in breast carcinoma fibroblastic cells and possibly implicated in tumor progression
63. Correlation between stromelysin-3 mRNA level and outcome of human breast cancer
64. Proteases as prognostic markers in cancer
65. Prognostic and predictive factors
66. Association between high concentrations of Mr 52000 cathepsin D and poor prognosis in primary human breast cancer
67. The urokinase plasminogen activator system as a target for prognostic studies in breast cancer
68. Plasminogen activator inhibitor-1 and prognosis in primary breast cancer
69. Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas
70. Plasminogen activator inhibitor type 1 in cytosolic tumor extracts predicts prognosis in low-risk breast cancer patients
71. Fibrinolytic pathways and the endothelium
72. Inhibition of receptor-bound urokinase by plasminogen-activator inhibitors
73. Plasminogen activator inhibitors: Hormonally regulated serpins
74. Type-1 plasminogen activator inhibitor in human breast carcinomas
75. The plasminogen activation system in human colon cancer: Messenger RNA for the inhibitor PAI-1 is located in endothelial cells in the tumor stroma
76. Increased proteolytic activity is responsible for the aberrant morphogenetic behavior of endothelial cells expressing the middle T oncogene
77. The product of the human c-erbB-2 gene: A 185-kilodalton glycoprotein with tyrosine kinase activity
78. ERBB2 oncogene in human breast cancer and its clinical significance
79. p53 and c-erbB-2 protein expression in breast carcinoma
80. Prevalence of amplification of the oncogenes c-myc, HER2/neu, and int-2 in one thousand human breast tumours: Correlation with steroid receptors
81. c-erbB2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases
82. Prognostic importance of c-erbB-2 expression in breast cancer
83. Prognostic value of c-erbB2 overexpression in axillary lymph node positive breast cancer. Results from a randomized adjuvant treatment protocol
84. c-erbB-2 Oncogene related to p53 expression, cell proliferation and prognosis in breast cancer
85. c-erbB2 Expression in correlation to other biological parameters of breast cancer
86. The prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers
87. Immunohisto-chemical detection of estrogen receptor in invasive human breast cancer: Correlation with heat shock proteins, pS2 and oncogene products
88. Oncogene amplification correlates with dense lymphocyte infiltration in human breast cancers: A role for hematopoietic growth factor release by tumor cells?
89. Structure and expression of c-erbB-2 and EGF receptor genes in inflammatory and non-inflammatory breast cancer: Prognostic significance
90. ERBB2 amplification in breast cancer with a high rate of proliferation
91. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
92. Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer. The influence of the pattern of immunostaining and adjuvant therapy
93. HER-2/neu oncogene protein and prognosis in breast cancer
94. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu
95. erbB-2 and Response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer
96. Efficacy and safety of Herceptin (humanized anti-HER2 antibody) as a single agent in 222 women with HER2 overexpression who relapsed following chemotherapy for metastatic breast cancer
97. Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2 +/MBC) markedly increases anticancer activity: a randomized, multinational controlled phase III trial